We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Amneal Pharmaceuticals Inc (AMRX) USD0.01 A

Sell:$7.10 Buy:$7.11 Change: $0.04 (0.57%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Change: $0.04 (0.57%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
Change: $0.04 (0.57%)
Market closed |  Prices as at close on 12 June 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.

Contact details

400 Crossing Boulevard, 3rd Floor
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.17 billion
Shares in issue:
460.77 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Chirag Patel
    President, Co-Chief Executive Officer, Co-Founder, Director
  • Chintu Patel
    Co-Chief Executive Officer, Co-Founder, Director
  • Anastasios Konidaris
    Chief Financial Officer, Executive Vice President
  • Nikita Shah
    Chief Human Resource Officer, Executive Vice President
  • Andrew Boyer
    Executive Vice President, Chief Commercial Officer - Generics
  • Gustavo Pesquin
    Executive Vice President, Chief Commercial Officer - Speciality
  • Jason Daly
    Senior Vice President, Chief Legal Officer and Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.